Clinical Advances in Hematology and Oncology : Impact Factor & More
eISSN: 1543-0790pISSN: 1543-0790
Share this on:
Key Metrics
CiteScore 
1.2
SJR
Q4Oncology
SNIP
0.67
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Clinical Advances in Hematology and Oncology Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | MILLENNIUM MEDICAL PUBLISHING, INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2003 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers in Clinical Advances in Hematology and Oncology
Update on immune checkpoint inhibition for cervical cancer.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
The addition of PARP inhibition to androgen receptor pathway inhibition in metastatic hormone-sensitive prostate cancer.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
How to implement DPYD genotyping into practice.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
Periprocedural management of patients on antithrombotic therapy.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
Cabozantinib plus nivolumab as first-line therapy for advanced renal cell carcinoma with bone metastases: a clinical case report.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
Hemophagocytic lymphohistiocytosis: new grading classification and targeted therapies.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
Update on immune checkpoint inhibition for cervical cancer.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
The addition of PARP inhibition to androgen receptor pathway inhibition in metastatic hormone-sensitive prostate cancer.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
How to implement DPYD genotyping into practice.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
Periprocedural management of patients on antithrombotic therapy.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
Cabozantinib plus nivolumab as first-line therapy for advanced renal cell carcinoma with bone metastases: a clinical case report.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
Hemophagocytic lymphohistiocytosis: new grading classification and targeted therapies.
- 1 May 2026
- Clinical advances in hematology & oncology : H&O
FAQs on Clinical Advances in Hematology and Oncology
How long has Clinical Advances in Hematology and Oncology been actively publishing? 
What is the publishing frequency of Clinical Advances in Hematology and Oncology?
How many articles did Clinical Advances in Hematology and Oncology publish last year?
What is the eISSN & pISSN for Clinical Advances in Hematology and Oncology?
What is Citescore for Clinical Advances in Hematology and Oncology?
What is SNIP score for Clinical Advances in Hematology and Oncology?
What is the SJR for Clinical Advances in Hematology and Oncology?
Who is the publisher of Clinical Advances in Hematology and Oncology?
